| 陆佳,姚福生,徐海涛.超小剂量地西他滨治疗骨髓增生异常综合征和急性髓系白血病11例疗效观察[J].安徽医药,2018,22(5):986-988. |
| 超小剂量地西他滨治疗骨髓增生异常综合征和急性髓系白血病11例疗效观察 |
| Effect and adverse effects of ultra-low-dose decitabine regimen in the treatment of myelodysplastic syndrome and acute myeloid leukemia:An analysis of 11 cases |
| 投稿时间：2017-06-17 |
| DOI： |
| 中文关键词: 骨髓增生异常综合征 地西他滨 急性髓系白血病 疗效 |
| 英文关键词: myelodysplastic syndrome decitabine acute myeloid leukemia efficiency |
| 基金项目: |
|
| 摘要点击次数: 2319 |
| 全文下载次数: 1133 |
| 中文摘要: |
| 目的 分析超小剂量地西他滨治疗骨髓增生异常综合征(MDS)和急性髓系白血病(AML)的近期临床疗效和不良反应。 方法 观察11例接受超小剂量地西他滨治疗的患者临床疗效和不良反应发生率。其中,6例中危-Ⅰ组MDS患者接受地西他滨 5~7 mg·m-2·d-1,连用5~6 d的超小剂量方案；2例中危-Ⅱ组和1例高危组MDS患者接受地西他滨联合半程CAG治疗方案；1例高危组MDS患者接受地西他滨联合HA治疗方案；1例AML患者接受地西他滨联合DA治疗方案。 结果 11例接受地西他滨治疗的患者中,3例完全缓解,4例部分缓解,1例血液学改善,2例疾病无进展,1例死亡。总有效率为72.7%,完全缓解率为27.3%。3例患者出现肺部感染,1例出现消化道出血。3例出现Ⅱ级血液学不良反应,3例出现Ⅲ级血液学不良反应,均治疗后好转。 结论 超小剂量地西他滨治疗方案在中高危组 MDS 患者中安全有效,耐受性好,且感染及血液学不良反应发生率较低,可在临床进一步推广。 |
| 英文摘要: |
| Objective To analyze the short-term therapeutic effect and adverse effects of ultra-low-dose decitabine regimen in the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia. Methods The clinical efficacy and the incidence of adverse reactions in 11 patients receiving ultra-low-dose decitabine were observed.Among these patients,6 intermediate-Ⅰ risk MDS patients were treated with decitabine 5~7 mg·m-2·d-1 once daily for 5 or 6 days for a course of treatment;2 intermediate-Ⅱ risk MDS patients and 1 high-risk MDS patient received DAC combined with half-way CAG program;1 case of high-risk MDS received DAC combined with HA program;one case of acute myeloid leukemia receivied DAC combined with DA regimen. Results Of the 11 patients receiving decitabine,3 cases had complete remission,4 cases had partial remission,1 case had hematological improvement,2 cases had no disease progression,and 1 case died.The overall response rate (ORR) was 72.7% and the remission rate (CR) was 27.3%.There were 3 cases with pulmonary infection,1 case of gastrointestinal bleeding,3 cases of grade 2 hematologic adverse reactions,3 cases of grade III hematologic adverse reactions,and all of them improved after treatment. Conclusions The ultra-low-dose decitabine treatment regimen is safe,effective,well tolerated and has a low incidence of infection and hematological adverse reactions in MDS patients with high-risk group,all of which suggests that it can be further promoted in clinical practice. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
